报告要点 [Table_Summary] 伴随着创新药企业 A/H 上市和增发充沛资金，二级市场创新药估值重塑和一级退出通道打通带 来中国生物医药投融资生态逐渐走向正循环，创新药对外 BD 涌现为研发投入注入新的资金来 源并拉动行业整体研发投入意愿，中国创新药研发投入景气度或渐趋改善，随之带来创新药产 业链进入新一轮景气周期。 分析师及联系人 [Table_Author] 丨证券研究报告丨 行业研究丨专题报告丨医疗保健 [Table_Title] 创新链系列——中国创新药研发投入景气度指 标 2025 年 12 月跟踪及全年总结 彭英骐 万梦蝶 SAC：S0490524030005 SAC：S0490525050001 SFC：BUZ392 请阅读最后评级说明和重要声明 %% %% %% %% research.95579.com 1 医疗保健 cjzqdt11111 [Table_Title 创新链系列2] ——中国创新药研发投入景气度指 标 2025 年 12 月跟踪及全年总结 [Table_Summary2] 2025 年 12 月前瞻性指标趋势 1、IPO 募集资金：2025 年 12 月医药港股 I ...

Group 1: Industry Insights - The Ministry of Industry and Information Technology (MIIT) has warned against irrational competition in the lithium battery industry, convening a meeting with 16 major companies to discuss regulatory measures [1] - The State Administration for Market Regulation (SAMR) has interviewed six leading photovoltaic companies regarding monopoly risks and has mandated corrective actions by January 20 [1] - Guangzhou is accelerating the construction of liquid rocket assembly and testing bases, focusing on reusable rocket technology to enhance national aerospace capabilities [2] Group 2: Company Announcements - MiniMax is set to list on the Hong Kong Stock Exchange on January 9, with a pricing result of HKD 165 per share, and its dark market performance showed a 26.8% increase [3] - Zhong UAV has signed a contract exceeding RMB 100 million for drone systems, which is expected to positively impact its financial performance [4][5] - TianNeng Co. plans to use up to RMB 12 billion of its idle funds for low-risk financial investments, which has been approved by its board [5] - Hu Silicon Industry's major shareholder, the National Integrated Circuit Industry Investment Fund, has reduced its stake by 0.2% [5] - Yongxi Electronics expects a net profit increase of 13.08% to 50.77% for 2025, driven by growth in the semiconductor industry and improved product structure [6] - BiYi Micro has set an initial transfer price of RMB 36.29 per share for its stock, with a subscription multiple of 6.99 times [7] - ZhiXiang JinTai's application for conditional approval of its GR1803 injection has been accepted by the National Medical Products Administration [8] - Zejing Pharmaceutical's injection of human thyroid-stimulating hormone beta has been approved for market entry, enhancing its product line [9] - Mengke Pharmaceutical has received a patent term extension for its core product, significantly improving its market competitiveness [9] - Chip Source Micro has reported a 30% stock price fluctuation, confirming normal business operations [9] - Jiyu Pharmaceutical has completed nearly RMB 2 billion in Series A financing, focusing on innovative drug development [10] - Yiwei Aerospace has completed a million-level angel round financing, aimed at developing space computing systems [10]

Core Viewpoint - The A-share market is expected to continue its recovery in 2026, particularly in the pharmaceutical sector, driven by three main factors: the ongoing trend of international expansion, stabilization of domestic demand alongside macroeconomic recovery, and overall valuations remaining below historical averages [2][3]. Group 1: Pharmaceutical Sector Performance - In 2025, the pharmaceutical sector showed a structural recovery, with the innovation drug segment being the standout performer, while other areas like medical devices and services lagged [1][3]. - The innovation drug sector experienced significant growth primarily from March to July 2025, followed by a correction starting in September due to rapid price increases and overvaluation [1][3]. - The overall performance of the pharmaceutical sector in 2025 was characterized by a 10% increase in the Shenwan Biopharmaceutical Index, which underperformed compared to the CSI 300 [1]. Group 2: Investment Logic and Trends - The investment logic for innovative drugs in A-shares, H-shares, and U.S. stocks is fundamentally similar, focusing on drug technology characteristics, global competition, and valuation factors influenced by policies and interest rates [2][8]. - The Chinese innovative drug industry is still in its early stages, with significant growth potential, and the investment focus in A-shares and H-shares is more on policy, capital market cycles, and industry mapping [2][8]. - The trend of "going global" for innovative drugs and medical devices is accelerating, which is expected to enhance the competitive edge of Chinese companies in various disease areas, especially oncology [3][4]. Group 3: Future Outlook and Risks - The pharmaceutical sector is anticipated to maintain its upward trend in 2026, supported by the deepening internationalization of the industry and improved domestic demand due to economic recovery [2][3]. - Key risks to monitor include potential unexpected tightening of medical insurance cost controls, U.S. healthcare reforms, and the pace of interest rate changes by the Federal Reserve [3][9]. - The valuation of the pharmaceutical sector remains below the historical average of the past 15 years, indicating a relative advantage for investors [3].

Market Overview - A-shares experienced narrow fluctuations with the Shanghai Composite Index slightly declining but recording 15 consecutive days of gains [1] - The total trading volume in the Shanghai and Shenzhen markets reached 2.8 trillion yuan, a slight decrease from the previous trading day, but has remained above 2.5 trillion yuan for four consecutive days [1] - Over 3,700 stocks in the market rose, with 111 stocks hitting the daily limit [1] Sector Performance - The commercial aerospace sector saw a surge, with stocks like Aerospace Nanhai and Hailanxin hitting the 20% limit up [1] - The military industry ETF, Huabao (512810), rose over 4%, marking its largest single-day increase in nearly six months and reaching a new high since its listing in August 2016 [1][6] - The popular general aviation ETF, Huabao (159231), also increased by over 4%, setting a new record since its listing, with a net subscription of 14 million units in a single day [1] Policy Impact - The Ministry of Industry and Information Technology and seven other departments issued the "Implementation Opinions on the Special Action of 'Artificial Intelligence + Manufacturing'," focusing on the domestic AI industry chain [1] - Following this policy announcement, the AI-related ETFs, including the Huabao Science and Technology AI ETF (589520) and the Big Data ETF (516700), saw increases of over 1% [1][12] Stock Highlights - The military ETF Huabao (512810) recorded a trading volume of 883 million yuan, with a notable increase in net inflow of funds into defense and military stocks, totaling 18.932 billion yuan [6][8] - Key stocks within the military ETF include Aerospace Nanhai, Hailanxin, and Aerospace Electronics, which have seen significant trading volumes and price increases [5][10] Future Outlook - Dongguan Securities anticipates that the market will maintain upward momentum before the Spring Festival, suggesting that any short-term adjustments could present buying opportunities [2] - The overall market sentiment is expected to remain positive, with a focus on sectors such as dividends, TMT (Technology, Media, and Telecommunications), and consumer goods [2]

Group 1: Storage Market - The storage market is experiencing a "super bull market" driven by explosive AI inference demand and exponential growth in multimodal data, with prices significantly increasing [2][7] - The global DRAM market has seen prices rise rapidly since July 2025, with most categories increasing over 100%, and the price of a single 256G DDR5 server memory exceeding 40,000 yuan [2][7] - Major storage manufacturers are shifting production capacity towards HBM and DDR5, leading to limited supply of traditional memory, and cloud service providers are paying premiums far exceeding those of mobile manufacturers [2][7] - Capacity tightness is expected to last at least until the end of 2027 [2][7] Group 2: Commercial Aerospace - The commercial aerospace sector is witnessing a surge, with nearly 40 stocks hitting the daily limit up on January 8, driven by policy support and technological breakthroughs [2][7] - The construction of a large liquid rocket assembly and recovery base by Arrow Yuan Technology in Zhejiang Qiantang has commenced [2][7] - Analysts believe that the commercial aerospace industry is entering a new era, with a need for legislative and procurement support to tackle cost reduction in reusable rockets [2][7] Group 3: Trade Relations - China has initiated an anti-dumping investigation into imported dichlorodihydrosilane from Japan, effective January 7, 2026, due to a rising trend in import quantities and a 31% cumulative price drop from 2022 to 2024 [2][7] - This investigation follows China's tightening of export controls on Japan, which has led to a decline in the Japanese stock market [2][7] - Estimates suggest that if rare earth exports are restricted, Japan's economy could suffer a loss of approximately 30 billion yuan within three months [2][7] Group 4: Monetary Policy - The People's Bank of China has emphasized the continuation of a moderately loose monetary policy, focusing on promoting high-quality economic development and reasonable price recovery [8][9] - Experts anticipate that the first round of interest rate cuts and reserve requirement ratio reductions may occur before the Spring Festival, with ample room for monetary policy adjustments in 2026 [8][9] Group 5: Innovation in Pharmaceuticals - The A-share innovative drug sector is showing signs of recovery, with the Hong Kong market performing even better, as valuations have entered an attractive range [8][9] - Fund managers believe that innovative drugs will remain a key investment theme in 2026, supported by continuous positive catalysts and improved overseas liquidity [8][9] - The emergence of brain-computer interface concepts may also boost the medical device sector, with "going overseas" capabilities becoming a core criterion for selecting companies [8][9] Group 6: Nuclear Fusion Technology - The controlled nuclear fusion sector is experiencing renewed strength, with multiple stocks hitting the daily limit up following breakthroughs in China's nuclear fusion technology [10] - The EAST experiment has confirmed the existence of a density-free zone in the Tokamak, and the upcoming implementation of the Atomic Energy Law will support controlled thermonuclear fusion [10] - Global investment in the fusion industry is rapidly increasing, with the market expected to reach $496.55 billion by 2030 [10] Group 7: AI and Manufacturing Integration - Eight departments, including the Ministry of Industry and Information Technology, have issued implementation opinions for the "AI + Manufacturing" initiative, aiming for secure and reliable supply of key AI technologies by 2027 [10] - The initiative will promote breakthroughs in key technologies such as smart chips and accelerate the application of AI across various manufacturing sectors [10]

Core Insights - The core viewpoint of the article emphasizes that the surge in innovative drug licensing and BD transactions has significantly driven the stock price explosion in the pharmaceutical sector, with total transaction amounts reaching $135.655 billion in 2025, marking a 161% increase from 2024 [1][4]. Group 1: Market Performance - The Hong Kong biopharmaceutical sector has rebounded strongly in 2025, with the Hang Seng Healthcare Index (HSHCI) rising by 76%, outperforming the Hang Seng Index and the overall A-share biopharmaceutical sector, which saw a 25.64% increase [1]. - Southbound capital inflow reached a record high of HKD 1.4 trillion in 2025, with healthcare sector holdings increasing by 125.51% to HKD 540 billion, providing substantial liquidity to the market [1][3]. Group 2: Structural Differentiation - The structural differentiation within the biopharmaceutical sector is becoming more pronounced, with companies that have First-in-Class or Best-in-Class pipelines and stable BD revenue sources being favored, while those reliant on single core projects face valuation pressures [3]. - The CXO sector also performed well in 2025, benefiting from ongoing investments in innovative drugs, while the medical device and supplies sector showed solid performance due to stable cash flows [3]. Group 3: Policy and Regulatory Environment - The policy environment has been continuously optimized, with 76 innovative drugs approved for market entry by the National Medical Products Administration in 2025, significantly surpassing the 48 approvals in 2024 [5]. - The introduction of the first version of the innovative drug commercial insurance catalog marks a shift to a dual protection system of basic medical insurance and commercial health insurance, enhancing clinical medication standards and overall industry R&D returns [6]. Group 4: Future Outlook - The explosive growth in BD transactions and active IPOs is injecting strong cash flow and confidence into the biopharmaceutical industry, with expectations for leading companies like BeiGene to achieve profitability in 2026 [5]. - However, challenges remain, including potential market pressure from a wave of unlocks post-IPO lock-up periods and stricter regulatory scrutiny on IPO applications [7].

Group 1 - The core viewpoint is that China's innovative pharmaceuticals are strengthening their global competitiveness, with the past two years marking a significant period for international expansion and record-high licensing transactions in terms of quantity and value [1] - After the successful completion of business development (BD) transactions, the initiation of Phase III clinical trials overseas is expected to enhance the certainty of product listings, leading to an increase in valuations based on potential peak sales and improved success rates [1] - The domestic CRO (Contract Research Organization) orders are experiencing a trend of simultaneous growth in both volume and price, benefiting from the international expansion of innovative drugs and a stabilization in financing, with project volumes expected to achieve double-digit growth, indicating an improvement cycle in 2026 [1] Group 2 - In terms of overseas demand, China's CDMO (Contract Development and Manufacturing Organization) remains irreplaceable in the global supply chain, with steady growth in small molecule CDMO orders and rapid increases in orders for new molecular fields such as ADC (Antibody-Drug Conjugates) and peptides, with clinical and commercialization projects expected to gradually ramp up [1] - The medical device industry is accelerating innovation and internationalization, with an anticipated improvement in 2026, and a moderate trend in the collection policies for consumables and IVD (In Vitro Diagnostics), providing domestic manufacturers with opportunities for volume growth through price adjustments [1] - The Guotai Innovative Drug ETF (517110) tracks the SHS Innovative Drug Index (931409), which selects companies involved in the research and production of innovative drugs from both mainland and Hong Kong markets, covering 50 representative securities and focusing on the innovative drug industry chain [1]

Core Viewpoint - The A-share market is expected to continue its recovery in 2026, particularly in the pharmaceutical sector, driven by three main factors: the ongoing trend of international expansion, stabilization of domestic demand alongside macroeconomic recovery, and the overall valuation of the sector remaining below historical averages [5][6]. Group 1: Pharmaceutical Sector Performance - In 2025, the pharmaceutical sector showed an overall recovery, but with significant structural differences, as the Shenwan Biopharmaceutical Index rose by approximately 10%, underperforming the CSI 300 [4]. - The innovative drug sector was the standout performer, although its strong performance was not consistent throughout the year, experiencing a notable correction from September onwards due to rapid price increases earlier in the year [4][7]. - The valuation of representative indices like the Hang Seng Healthcare and Shenwan Chemical Pharmaceutical exceeded historical averages, necessitating a period of adjustment [4][7]. Group 2: Investment Logic and Trends - The investment logic for innovative drugs in A-shares and Hong Kong shares focuses on policy, capital market cycles, and industry and technology mapping, reflecting the relatively early stage of China's innovative drug industry [5][11]. - The global trend of Chinese innovative drugs is just beginning, with significant competitive advantages in areas like molecular screening and clinical trials, particularly in oncology [8][11]. - The normalization of medical insurance negotiations and the trend of "going global" are identified as two key pricing logic factors for new drugs [9]. Group 3: Future Outlook and Considerations - The pharmaceutical sector is expected to maintain its upward trend in 2026, supported by the deepening trend of internationalization, improved domestic demand, and favorable valuations [6][8]. - Key considerations for evaluating new drugs include their efficacy compared to existing therapies and the competitive landscape, which significantly impacts their commercial viability [9]. - AI's potential impact on the pharmaceutical industry is recognized, particularly in drug discovery and clinical trials, with a focus on tangible outcomes rather than speculative hype [10].

Core Insights - The investment landscape in 2025 has seen significant changes, with Chinese technology leading equity gains and the Shanghai Composite Index surpassing 4000 points for the first time in a decade [1][9] - Long-term capital, including insurance funds, is entering the market, enhancing value investment opportunities [1][9] - The trend of index-based investment is rising, with index funds becoming a primary tool for market allocation [1][9] - The complexity of bond investments is increasing, prompting a broader asset allocation strategy [1][9] Policy and Economic Outlook - The 20th National Congress and the Central Economic Work Conference have set a framework for the "14th Five-Year Plan," indicating a proactive fiscal and monetary policy for 2026 [2][10] - The fiscal policy is expected to maintain necessary deficits, while monetary policy will focus on flexibility and efficiency, likely continuing a low-interest-rate environment [2][10] - The equity risk premium (ERP) has decreased from 90% to around 50% since April 2025, indicating that equity assets still have upward potential [2][10] Market Structure and Capital Flow - The capital market's institutional framework has strengthened since 2025, supporting long-term investment policies and enhancing market stability [3][11] - The acceleration of medium to long-term capital inflows is anticipated, fostering a friendly policy environment for the capital market [3][11] Sector-Specific Insights - The technology sector has gained significant attention, with notable events highlighting China's advancements in technology and innovation [4][12] - The AI industry is expected to drive market growth, with a focus on performance and profitability of major tech companies [5][12] - The domestic innovative pharmaceutical sector has seen rapid growth, with 76 new drugs approved in 2025 and record-high licensing deals exceeding $130 billion [5][12] Multi-Asset Investment Strategy - The investment strategy is shifting towards a broader multi-asset approach, utilizing FOF strategies and index investment tools [6][13] - The outlook for global risk assets is positive, with expectations of a "slow bull" market in domestic equities and rising prices for major commodities [6][13] - Index funds are increasingly becoming a vital tool for multi-asset allocation, with a focus on structural opportunities in A-shares and Hong Kong stocks [6][14] Future Development Plans - The company aims to advance its three major business strategies: "Global Tech Innovators," "Index Specialists," and "Fixed Income Experts," to establish itself as a multi-asset management expert [7][14]

Core Viewpoint - The Chinese emerging technology industry is in the early stage of its lifecycle, with high valuations and significant innovation advantages expected to drive market capitalization growth for leading companies; the manufacturing and consumption industries are more mature, with solid global competitiveness and potential for valuation increases [3][66]. Group 1: Technology Industry Comparison - The overall lifecycle of China's emerging technology industry is early, with optimistic growth expectations reflected in valuations for AI hardware and innovative pharmaceuticals [72]. - The semiconductor, innovative pharmaceuticals, and communication equipment sectors show high valuations compared to international leaders, indicating market optimism for rapid profit growth and catching up [9][72]. - Internet companies exhibit weaker profitability and lower relative valuations compared to international counterparts, while consumer electronics have a notable overseas revenue share and moderate valuations [9][72]. Group 2: Advanced Manufacturing Comparison - The advanced manufacturing sector in China is relatively mature, with strong global competitiveness and significant valuation advantages compared to international leaders [68][98]. - The lithium battery sector leads in scale and profitability, with head companies generally having lower valuations than their international counterparts, indicating a strong cost-performance ratio [68][40]. - High-end equipment and new materials industries have profitability comparable to international leaders, but their global expansion potential remains significant [68][40]. Group 3: Consumer Industry Comparison - The product consumption sector in China shows strong profitability, but its growth is heavily reliant on domestic demand, leading to lower global competitiveness compared to international leaders [68][49]. - Service consumption is still in the early development stage, with lower scale and profitability compared to international leaders, but it has substantial growth potential as the economic structure transforms [68][49]. - Overall, the consumer sector has a relatively high cost-performance ratio, with opportunities arising from the transformation of consumption structure and the growth of service consumption leaders [68][49]. Group 4: Investment Recommendations - Recommendations include leading companies in electric new energy, transportation equipment, communication devices, electronics, and service consumption sectors, which are expected to benefit from strong innovation advantages and global expansion potential [69][60].